Veeva Systems (VEEV) Stock Price, News & Analysis

Company Overview

Veeva Systems Inc. is a leading provider of cloud-based software solutions designed specifically for the global life sciences industry. Founded in 2007 and headquartered in Pleasanton, California, the company delivers applications that streamline critical processes across research, development, quality, regulatory, and commercial functions. By leveraging a modern, multitenant cloud architecture, Veeva aims to help biotechnology, pharmaceutical, and medical device companies accelerate time to market, maintain compliance, and improve overall operational efficiency.

The company’s flagship offering, the Veeva Vault platform, provides a unified content management and data repository for regulated documents and workflows. Vault supports a wide range of use cases such as clinical trial documentation, regulatory submissions, quality management, and safety reporting. In addition to Vault, Veeva’s commercial suite—which includes Veeva CRM and Veeva Commercial Cloud—enables life sciences organizations to manage customer relationships, deploy multichannel marketing campaigns, and gain actionable insights through integrated analytics.

Over time, Veeva has expanded its portfolio to address emerging industry needs in areas like real-world evidence collection, regulatory information management, and pharmacovigilance. The company serves customers of all sizes—from large multinational pharmaceutical firms to specialty and emerging biotech companies—across North America, Europe, Asia Pacific, Latin America, and other markets worldwide. Veeva’s solutions are tailored to meet regional regulatory requirements while supporting global collaboration and data integrity.

Peter Gassner, co-founder and chief executive officer, has led Veeva since its inception and guided its growth from a startup to a publicly traded company following its initial public offering in 2013. Under his leadership, Veeva continues to invest in research and development to expand its application suite and enhance platform capabilities. The company’s executive team combines deep expertise in life sciences and enterprise software, positioning Veeva to address the evolving challenges of highly regulated industries.

Key Stats

• Today's Range: $270.38 to $274.01
• 50-Day Range: $268.85 to $295.23
• 52-Week Range: $200.30 to $296.72
• Volume: 1.44 million shs
• Average Volume: 1.32 million shs
• Market Capitalization: $44.63 billion
• P/E Ratio: 56.08
• Dividend Yield: N/A
• Price Target: $299.88
• Consensus Rating: Moderate Buy

Veeva Systems Stock Analysis - MarketRank™

Veeva Systems scored higher than 90% of companies evaluated by MarketBeat, and ranked 122nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veeva Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 16 buy ratings, 7 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Veeva Systems is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Veeva Systems has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.67%

Earnings Growth

Earnings for Veeva Systems are expected to grow by 6.67% in the coming year, from $4.35 to $4.64 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veeva Systems is 56.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 277.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veeva Systems is 56.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.08.

Price to Earnings Growth Ratio

Veeva Systems has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Veeva Systems has a P/B Ratio of 6.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.87% of the outstanding shares of Veeva Systems have been sold short.

Short Interest Ratio / Days to Cover

Veeva Systems has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Veeva Systems has recently increased by 1.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veeva Systems does not currently pay a dividend.

Dividend Growth

Veeva Systems does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.9 / 5
• Environmental Score: -0.79

Percentage of Shares Shorted

2.87% of the outstanding shares of Veeva Systems have been sold short.

Short Interest Ratio / Days to Cover

Veeva Systems has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Veeva Systems has recently increased by 1.52%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.19

News Sentiment

Veeva Systems has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 40 news articles for Veeva Systems this week, compared to 31 articles on an average week.

Search Interest

25 people have searched for VEEV on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.

MarketBeat Follows

18 people have added Veeva Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Veeva Systems insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $394,217.00 in company stock.

Percentage Held by Insiders

10.30% of the stock of Veeva Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.20% of the stock of Veeva Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VEEV Stock Analysis - Frequently Asked Questions

How have VEEV shares performed this year?

Veeva Systems' stock was trading at $210.25 on January 1st, 2025. Since then, VEEV shares have increased by 29.9% and is now trading at $273.1220.

How were Veeva Systems' earnings last quarter?

Veeva Systems Inc. (NYSE:VEEV) announced its earnings results on Wednesday, May, 28th. The technology company reported $1.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.74 by $0.23. The firm's revenue was up 16.7% on a year-over-year basis.
Read the conference call transcript.

Does Veeva Systems have any subsidiaries?

Veeva Systems subsidiaries include these companies: Veeva RTSM, Veracity Logic, Learnaboutgmp, Physicians World, Veeva Crossix, Zinc Ahead Ltd, Selligy, and AdvantageMS.

Who are Veeva Systems' major shareholders?

Top institutional investors of Veeva Systems include Vanguard Group Inc. (9.16%), Alliancebernstein L.P. (3.49%), State Street Corp (2.10%) and JPMorgan Chase & Co. (2.03%). Insiders that own company stock include Matthew J Wallach, Thomas D Schwenger, Alan Mateo, Eleni Nitsa Zuppas, Paul Edward Chamberlain, Paul J Sekhri, Michele O'connor, Jonathan Faddis, Timothy S Cabral, Mary Lynne Hedley, Priscilla Hung and Peter P Gassner.
View institutional ownership trends.

How do I buy shares of Veeva Systems?

Shares of VEEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veeva Systems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veeva Systems investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 5/28/2025
• Today: 9/06/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Computer Software
• Current Symbol: NYSE:VEEV
• CIK: 1393052
• Web: www.veeva.com
• Phone: (925) 452-6500
• Fax: 925-452-6504
• Employees: 7,291
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Veeva Systems: $299.88
• High Price Target: $355.00
• Low Price Target: $200.00
• Potential Upside/Downside: +9.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.87
• Trailing P/E Ratio: 56.08
• Forward P/E Ratio: 62.79
• P/E Growth: 2.1
• Net Income: $714.14 million
• Net Margins: 27.29%
• Pretax Margin: 35.43%
• Return on Equity: 13.72%
• Return on Assets: 11.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.57
• Quick Ratio: 4.60

Sales & Book Value

• Annual Sales: $2.97 billion
• Price / Sales: 15.04
• Cash Flow: $4.82 per share
• Price / Cash Flow: 56.63
• Book Value: $40.62 per share
• Price / Book: 6.72

Miscellaneous

• Outstanding Shares: 163,412,000
• Free Float: 146,581,000
• Market Cap: $44.63 billion
• Optionable: Optionable
• Beta: 0.95